ANXA2 was reported to prevent β-catenin phosphorylation and degradation by binding glycogen synthase kinase 3β (GSK3β) and disrupting the formation of the GSK3β/β-catenin complex in hepatocellular carcinoma cells 8. Here, ANXA2 is linked to hepatocellular carcinoma.